MRVI Q3 2023 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$67M-65.0% YoY

Gross Profit

$30M45.1% margin

Operating Income

-$15M-23.1% margin

Net Income

-$6M-9.7% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

-3.0%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

-$2M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$1.4B

Stockholders' Equity

$519M

Cash & Equivalents

$580M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$67M	$191M	-65.0%
Gross Profit	$30M	$153M	-80.3%
Operating Income	-$15M	$117M	-113.2%
Net Income	-$6M	$44M	-114.5%

Revenue Segments

Nucleic Acid Production Segment

$51M77%

Biologics Safety Testing Segment

$16M23%

Geographic Segments

North America

$35M52%

Asia Pacific

$25M37%

EMEA

$8M11%

Latin And Central America

$105,0000%